Whether Helicobacter pylori 'test and treat' or empirical acid suppression is preferred for the initial management of uncomplicated dyspepsia is controversial.
Dr Ford and colleagues from Canada conducted a meta-analysis of randomized controlled trials of 'test and treat' vs empirical acid suppression in adults with uncomplicated dyspepsia in primary care.
|The weighted mean difference in costs was -£28.91|
|Alimentary Pharmacology & Therapeutics|
The team evaluated original data sets for analysis.
The team examined effect of management strategy on symptom status and dyspepsia-related resource use at 12-month follow-up by pooling symptom and cost data.
The researchers obtained the relative risk of remaining symptomatic at 12 months and weighted mean difference in costs between the 2 strategies with 95% confidence intervals.
The researchers identified 3 eligible randomized controlled trials containing 1547 patients, of whom 791 were assigned to 'test and treat'.
There was no difference detected in symptom-cure at 12 months.
There was a nonsignificant trend towards cost-savings with 'test and treat'.
The weighted mean difference in costs was -£28.91.
Dr Ford's team concluded, "There was little difference in symptom-resolution or costs between the 2 strategies."
"A combination of patient and physician preference should determine the initial approach to the management of uncomplicated dyspepsia."